Blair William & Co. IL Decreases Stake in Insulet Co. (NASDAQ:PODD)

Blair William & Co. IL lessened its position in shares of Insulet Co. (NASDAQ:PODDFree Report) by 51.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,176 shares of the medical instruments supplier’s stock after selling 166,510 shares during the quarter. Blair William & Co. IL owned about 0.23% of Insulet worth $25,546,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP grew its holdings in Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 92 shares in the last quarter. BluePath Capital Management LLC purchased a new position in Insulet during the 3rd quarter valued at approximately $31,000. First Manhattan Co. purchased a new position in Insulet during the 4th quarter valued at approximately $35,000. Massmutual Trust Co. FSB ADV grew its holdings in Insulet by 228.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 263 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 183 shares in the last quarter. Finally, HM Payson & Co. bought a new stake in shares of Insulet in the 3rd quarter valued at approximately $48,000.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 20,000 shares of Insulet stock in a transaction on Monday, November 13th. The stock was sold at an average price of $164.33, for a total transaction of $3,286,600.00. Following the completion of the sale, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $421,835.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on PODD. Piper Sandler lowered their price objective on Insulet from $325.00 to $250.00 and set an “overweight” rating for the company in a research note on Friday, November 3rd. SVB Leerink began coverage on Insulet in a research note on Monday, October 16th. They issued an “outperform” rating and a $184.00 price objective for the company. Morgan Stanley raised Insulet from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $185.00 to $234.00 in a research note on Monday, December 4th. Stifel Nicolaus raised their price objective on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Finally, JPMorgan Chase & Co. lowered their price objective on Insulet from $325.00 to $162.00 and set an “overweight” rating for the company in a research note on Tuesday, October 17th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $250.40.

View Our Latest Report on Insulet

Insulet Trading Down 2.1 %

Shares of NASDAQ PODD opened at $192.55 on Friday. The company has a quick ratio of 2.35, a current ratio of 3.26 and a debt-to-equity ratio of 2.26. The business has a fifty day simple moving average of $202.87 and a two-hundred day simple moving average of $188.65. The firm has a market cap of $13.45 billion, a PE ratio of 112.60, a price-to-earnings-growth ratio of 2.13 and a beta of 1.05. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91.

Insulet Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.